InSite, Pharmacia, SSP Co. Ltd. deal

ISV regained rights from PHA to ISV-900, a DNA test that detects mutations with prognostic and diagnostic applications in glaucoma (see BioCentury, Nov. 22, 1999). ISV plans to bring the test to market next year. The companies’ collaboration to develop glaucoma treatment Diclofenac Eye (ISV-205) is unaffected (see BioCentury, Feb. 1, 1999). ...